Human Reactive Inflammatory Cytokine Antibody Sampler Kit #83636
Product Information
Kit Usage Information
Protocols
- 7074: Western Blotting
- 8184: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, Flow
- 8455: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence, Flow
- 12153: Western Blotting, Immunoprecipitation (Agarose)
- 12163: Western Blotting
- 12227: Western Blotting, Flow
- 12239: Western Blotting, Immunoprecipitation (Agarose)
- 12703: Western Blotting, Immunofluorescence, Flow
- 34819: Western Blotting
- 94407: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
Product Description
The Human Reactive Inflammatory Cytokine Antibody Sampler Kit provides an economical means of detecting inflammation-associated cytokine expression. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Background
Interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) are pro-inflammatory cytokines (1). IL-1α is produced by many cell types, including epithelial cells, monocytes, and macrophages (1,2). It is typically sequestered but can be released during necroptosis or inflammasome activation (3-5). IL-1α is active in both its uncleaved (pro-IL-1α) and cleaved forms and thus acts as an alarmin, initiating signaling through IL-1R1 (6). IL-1β is not active until it is cleaved (7,8). IL-1β expression is induced by inflammatory stimuli, including TLR ligands, IL-1β itself, and tumor necrosis factor-alpha (TNF-α) (1,9,10). IL-1β is primarily synthesized by activated monocytes and macrophages. It activates innate immune cells and polarizes CD4+ T cells toward T helper (Th) 1 and Th17 cells (10).
IL-2 is mainly produced by activated CD4+ and CD8+ T cells (11). IL-2 is a pro-inflammatory cytokine, promoting proliferation and activation of CD4+ and CD8+ T cells, B cells, and NK cells through binding the IL-2 receptor complex (11). At low doses, however, IL-2 can have anti-inflammatory effects (12).
IL-4, a cytokine produced by mast cells, basophils, and activated T cells, is an anti-inflammatory cytokine that promotes differentiation of naive T cells into Th2 lineage cells (13-15). In autoimmune conditions, IL-4 can play pro-inflammatory roles and is a therapeutic target (16).
IL-6, when interacting with soluble IL-6R and binding to gp130, has pro-inflammatory effects, but when interacting with membrane-bound IL-6R, it exerts anti-inflammatory effects (17). IL-6 regulates the acute phase response and is produced by T cells, macrophages, and endothelial cells (18,19). IL-6 can also prime macrophages for M2, or anti-inflammatory, states by upregulating IL-4R (20).
IL-8 is a neutrophil chemoattractant and is able to activate degranulation and respiratory burst (21-23). IL-8 is produced by T cells, monocytes, neutrophils, fibroblasts, endothelial cells, and others in response to inflammatory stimuli such as IL-1α/β and TNF-α (24). Beyond its chemotactic effects, IL-8 can play roles in cancer by promoting tumor angiogenesis and stimulating proliferation by activating NF-kB signaling (25,26).
IL-10 is an anti-inflammatory cytokine produced by various immune cells (27,28). IL-10 is often produced alongside pro-inflammatory cytokines in response to pathogens and limits damage to the host that can be caused by strong inflammatory responses (29). After binding to IL-10Rα, which complexes with IL-10Rβ, IL-10 activates Stat3, suppresses gp130 activity, and induces expression of transcriptional repressors of the inflammatory response (30).
Interferon-gamma (IFN-γ) is produced by T, B, NK, and antigen-presenting cells and has diverse pro- and anti-inflammatory functions (31). Its expression is induced by type I IFNs, IL-12, IL-15, and IL-18, and it acts through IFNγR1 and IFNγR2 to activate signaling through Stat1 (31). IFN-γ upregulates expression of major histocompatibility complex (MHC) class I and II, which help to activate cytotoxic CD8+ and CD4+ T cells, respectively (31-33). IFN-γ can also suppress pro-inflammatory cytokine expression and promote tumor cell apoptosis by upregulating expression of several caspases (31,34).
TNF-α is a pro-inflammatory mediator secreted by various subsets of immune cells, including T cells, B cells, NK cells, and macrophages (35). In the context of certain autoimmune diseases, and in antigen presentation, however, TNF-α can be immunosuppressive (36,37). TNF-α expression is induced by various stimuli, including IL-1β, IFN-γ, and microbial infections. Depending on downstream signaling checkpoints through MAPK, NF-kB, and caspase-8, it can promote both inflammatory gene expression and apoptosis, necroptosis, and pyroptosis (38-41).
IL-2 is mainly produced by activated CD4+ and CD8+ T cells (11). IL-2 is a pro-inflammatory cytokine, promoting proliferation and activation of CD4+ and CD8+ T cells, B cells, and NK cells through binding the IL-2 receptor complex (11). At low doses, however, IL-2 can have anti-inflammatory effects (12).
IL-4, a cytokine produced by mast cells, basophils, and activated T cells, is an anti-inflammatory cytokine that promotes differentiation of naive T cells into Th2 lineage cells (13-15). In autoimmune conditions, IL-4 can play pro-inflammatory roles and is a therapeutic target (16).
IL-6, when interacting with soluble IL-6R and binding to gp130, has pro-inflammatory effects, but when interacting with membrane-bound IL-6R, it exerts anti-inflammatory effects (17). IL-6 regulates the acute phase response and is produced by T cells, macrophages, and endothelial cells (18,19). IL-6 can also prime macrophages for M2, or anti-inflammatory, states by upregulating IL-4R (20).
IL-8 is a neutrophil chemoattractant and is able to activate degranulation and respiratory burst (21-23). IL-8 is produced by T cells, monocytes, neutrophils, fibroblasts, endothelial cells, and others in response to inflammatory stimuli such as IL-1α/β and TNF-α (24). Beyond its chemotactic effects, IL-8 can play roles in cancer by promoting tumor angiogenesis and stimulating proliferation by activating NF-kB signaling (25,26).
IL-10 is an anti-inflammatory cytokine produced by various immune cells (27,28). IL-10 is often produced alongside pro-inflammatory cytokines in response to pathogens and limits damage to the host that can be caused by strong inflammatory responses (29). After binding to IL-10Rα, which complexes with IL-10Rβ, IL-10 activates Stat3, suppresses gp130 activity, and induces expression of transcriptional repressors of the inflammatory response (30).
Interferon-gamma (IFN-γ) is produced by T, B, NK, and antigen-presenting cells and has diverse pro- and anti-inflammatory functions (31). Its expression is induced by type I IFNs, IL-12, IL-15, and IL-18, and it acts through IFNγR1 and IFNγR2 to activate signaling through Stat1 (31). IFN-γ upregulates expression of major histocompatibility complex (MHC) class I and II, which help to activate cytotoxic CD8+ and CD4+ T cells, respectively (31-33). IFN-γ can also suppress pro-inflammatory cytokine expression and promote tumor cell apoptosis by upregulating expression of several caspases (31,34).
TNF-α is a pro-inflammatory mediator secreted by various subsets of immune cells, including T cells, B cells, NK cells, and macrophages (35). In the context of certain autoimmune diseases, and in antigen presentation, however, TNF-α can be immunosuppressive (36,37). TNF-α expression is induced by various stimuli, including IL-1β, IFN-γ, and microbial infections. Depending on downstream signaling checkpoints through MAPK, NF-kB, and caspase-8, it can promote both inflammatory gene expression and apoptosis, necroptosis, and pyroptosis (38-41).
- Garlanda, C. et al. (2013) Immunity 39, 1003-18.
- Palomo, J. et al. (2015) Cytokine 76, 25-37.
- Dinarello, C.A. (2018) Immunol Rev 281, 8-27.
- Cohen, I. et al. (2010) Proc Natl Acad Sci USA 107, 2574-9.
- Tsuchiya, K. et al. (2021) Cell Rep 34, 108887.
- Malik, A. and Kanneganti, T.D. (2018) Immunol Rev 281, 124-137.
- Thornberry, N.A. et al. (1992) Nature 356, 768-74.
- Cerretti, D.P. et al. (1992) Science 256, 97-100.
- Dinarello, C.A. (2011) Blood 117, 3720-32.
- Bent, R. et al. (2018) Int J Mol Sci 19, 2155.
- Liao, W. et al. (2011) Curr Opin Immunol 23, 598-604.
- Zhang, J.Y. et al. (2022) Nat Commun 13, 7324.
- Yokota, T. et al. (1986) Proc Natl Acad Sci USA 83, 5894-8.
- Grabstein, K. et al. (1986) J Exp Med 163, 1405-14.
- Kopf, M. et al. (1993) Nature 362, 245-8.
- Gärtner, Y. et al. (2023) Pharmacol Ther 242, 108348.
- Scheller, J. et al. (2011) Biochim Biophys Acta 1813, 878-88.
- Heinrich, P.C. et al. (1998) Biochem J 334 (Pt 2), 297-314.
- Heinrich, P.C. et al. (1998) Z Ernahrungswiss 37 Suppl 1, 43-9.
- Mauer, J. et al. (2014) Nat Immunol 15, 423-30.
- Payne, A.S. and Cornelius, L.A. (2002) J Invest Dermatol 118, 915-22.
- Brat, D.J. et al. (2005) Neuro Oncol 7, 122-33.
- Mukaida, N. (2003) Am J Physiol Lung Cell Mol Physiol 284, L566-77.
- Baggiolini, M. and Clark-Lewis, I. (1992) FEBS Lett 307, 97-101.
- Zhang, B. et al. (2015) Cancer Biol Ther 16, 898-911.
- Fousek, K. et al. (2021) Pharmacol Ther 219, 107692.
- Moore, K.W. et al. (2001) Annu Rev Immunol 19, 683-765.
- Gabryšová, L. et al. (2014) Curr Top Microbiol Immunol 380, 157-90.
- Saraiva, M. and O'Garra, A. (2010) Nat Rev Immunol 10, 170-81.
- Saraiva, M. et al. (2020) J Exp Med 217, e20190418.
- Castro, F. et al. (2018) Front Immunol 9, 847.
- Curtsinger, J.M. et al. (2012) J Immunol 189, 659-68.
- Akbar, S.M. et al. (1996) Immunology 87, 519-27.
- Mühl, H. and Pfeilschifter, J. (2003) Int Immunopharmacol 3, 1247-55.
- Aggarwal, B.B. (2003) Nat Rev Immunol 3, 745-56.
- Kassiotis, G. and Kollias, G. (2001) J Exp Med 193, 427-34.
- Masli, S. and Turpie, B. (2009) Immunology 127, 62-72.
- Bethea, J.R. et al. (1992) J Neuroimmunol 36, 179-91.
- Vila-del Sol, V. et al. (2008) J Immunol 181, 4461-70.
- Rahman, M.M. and McFadden, G. (2006) PLoS Pathog 2, e4.
- van Loo, G. and Bertrand, M.J.M. (2023) Nat Rev Immunol 23, 289-303.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.